ABL Bio to Showcase Groundbreaking BBB Shuttle Technology at AAIC 2025

ABL Bio has announced its participation in the Alzheimer’s Association International Conference (AAIC) 2025, scheduled from July 27-31 in Toronto, Canada. The company plans to introduce its innovative blood-brain barrier (BBB) shuttle platform, "Grabody-B," marking a significant step forward in Alzheimer's disease treatment research.

Breaking Barriers in Neurodegenerative Disease Treatment

The BBB serves as a protective shield for the brain, but it also poses a challenge for drug delivery in neurodegenerative disease treatments. Following Roche's announcement of promising clinical data for "trontinemab," a BBB shuttle-based treatment, in 2023, the global spotlight has turned towards BBB shuttle technologies like Grabody-B.

Grabody-B: A Leap Forward in Brain Drug Delivery

ABL Bio's Grabody-B targets the Insulin-like Growth Factor-1 Receptor (IGF1R) to facilitate effective drug transport across the BBB. The platform's potential was further validated by a landmark technology transfer agreement with GlaxoSmithKline (GSK), worth up to 2.1401 billion pounds.

Lee Sang-hoon, CEO of ABL Bio, emphasized, "The attention on Grabody-B has surged, especially after our agreement with GSK. Our presentation will highlight the diverse brain delivery pathways of Grabody-B, as evidenced by non-clinical studies in mouse models."